C2i Genomics raises $100m in a Series B Casdin Capital led funding

Rido81 @Envato
SaaS News -C2i,-a-genomics-SaaS-product-to-detect-traces-of-cancer,-raises-$100M-Series-B-–-TechCrunch(source: SaaS Industry)
At a Glance

C2i Genomics, a cloud-based SaaS platform that performs highly precise cancer monitoring, has raised $100 million in Series B funding led by Casdin Capital today to accelerate clinical development and commercialize the company’s intelligence platform. Other investors such as NFX, Duquesne Family Office, Section 32 (Singapore), iGlobe Partners, and Driehaus Capital.

C2i prowess

Usually, after cancer surgeries take place, residual cancer cells may remain at insignificant levels, undetectable by MRI or X-ray scans. They can be detected using these conventional scans only after the tumor grows to a certain extent. Hence, a patient may be subjected to toxic chemotherapy radiation over the optimal level, or the patient’s cancer may return hence before doctors can trace it in time. Here is where C2i’s intelligence comes into the picture.

Being 100x more sensitive in its work, C2i’s “ultra-sensitive” test detects minute amounts of residual cancer cells. Doctors order a liquid biopsy using C2i’s technology (blood draw to look for DNA), from which genome sequencing is performed and uploaded to the C2i’s platform. The software on C2i then analyses the sample, identifies faint patterns of cancer growth or shrink, and relays the information.

Every lab having a sequencing machine can process samples on the platform. 

Asaf Zviran, CEO, CSO, and co-founder of C2i Genomics, who started the venture after his relatives didn’t survive cancer, talks about how C2i Genomics could change the way cancer treatment was done. Avoiding unnecessary surgeries, where sometimes a patient’s cancer-infected organs are removed, leaving them disabled, is a major goal for Zviran and his team.

“The biggest question in cancer treatment is, ‘Is it working?’ Some patients are getting the treatment they don’t benefit from, and they are suffering the side effects while other patients are not getting the treatment they need,” Zviran added.

Drawing knowledge from a research performed at the New York Genome Center (NYGC) and Weill Cornell Medicine (WCM) by Dr. Zviran, C2i’s ‘Genomics solution’ is yet to be approved by the Food and Drug Administration (FDA). However, it is already being used in clinical research and drug development research at various centers and hospitals such as the NYU Langone Health, National Center of Singapore, and the Aarhus University Hospital, and Lausanne University Hospital.

Previous News Post
Next News Post
Most Popular